# US 2016/0250235 A1 · Calcium glycerophosphate for treating and preventing respiratory diseases or conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250235 A1
- Document ID: US20160250235A1
- Status: Published application
- Kind: A1
- Application number: 15/151,574
- Filed: 2016-05-11
- Published: 2016-09-01
- Earliest claimed: 2007-08-30
- Assignees: Prelief Inc.
- Applicants: Prelief Inc.
- Inventors: Alan E. KLIGERMAN; Margaret T. WEIS
- Web page: https://patentgrep.com/patent/US20160250235A1

## CPC

- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 9/0043: {Nose}
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K 31/66: Phosphorus compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/06: Antiasthmatics
- A61M 15/009: {using medicine packages with incorporated spraying means, e.g. aerosol cans (pocket atomiser of the injector type A61M11/08)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Calcium glycerophosphate is found to be effective in treating and preventing a disease, disorder and/or condition of the respiratory system. The disease, disorder and/or condition is related to an obstructive or a restrictive condition of the respiratory airway. The disease, disorder and/or condition can be a respiratory airway inflammatory disease, a respiratory airway stenosis or a nasal cavity inflammatory disease, such as an asthma, a chronic obstructive pulmonary disease (COPD), an emphysema, a reactive airway disease (RADS), rhinitis, bronchitis, bronchiolitis, congestion, sinusitis, tonsillitis, or laryngitis, post-nasal drip (PND) and a related complication thereof, inflamed degranulating and non-degranulating mast cell activity, any irritation occasioning mucus secretion from goblet cells breathing difficulty, restriction, obstruction; airways constriction or closure or mucus interference with air passage; sleep apnea, snoring, inflammatory or non-inflammatory responses to an airborne or non-airborne allergen or irritant; nasal or non-nasal airway inflammation or irritation caused by a problem in any area of the body; and a physical damage to the respiratory system. Methods, compositions and devices are described for using calcium glycerophosphate to treat and prevent the disease, disorder and/or condition of the respiratory system.

## Claims

### Claim 1

A method of treating rhinitis, bronchial asthma, allergic asthma or chronic obstructive pulmonary disease (COPD) in a subject in need thereof, the method comprising nasally administering to the respiratory system of the subject an effective amount of calcium glycerophosphate in a dosage of about 440 μg to about 88 mg of calcium glycerophosphate per administration, wherein the effective amount of calcium glycerophosphate alleviates or improves the rhinitis, bronchial asthma, allergic asthma or chronic obstructive pulmonary disease (COPD) in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the calcium glycerophosphate is administered to the subject in a composition comprising about 0.05%-10% (w/w) calcium glycerophosphate.

### Claim 3 (depends on 2)

The method of claim 2, wherein the composition comprises about 0.5%-7.5% (w/w) calcium glycerophosphate.

### Claim 4 (depends on 1)

The method of claim 1, wherein the rhinitis is selected from the group consisting of allergic rhinitis, pollinosis, acute rhinitis, chronic rhinitis, hypertrophic rhinitis, and deflected septum.

### Claim 5 (depends on 1)

The method of claim 1, wherein the calcium glycerophosphate is administered to the subject by inhalation.

### Claim 6 (depends on 1)

The method of claim 1, wherein the calcium glycerophosphate is administered to the subject by intranasal instillation.

### Claim 7 (depends on 1)

The method of claim 1, wherein the calcium glycerophosphate is administered to the subject in a formulation of a powder, gel, microsphere, or suspension, and the formulation provides an extended release of calcium glycerophosphate into the airway of the subject, wherein the extended release results from a higher than soluble amount of the calcium glycerophosphate in a local environment of the respiratory system.

### Claim 8 (depends on 1)

The method of claim 1, wherein the calcium glycerophosphate is administered to the subject in a formulation that provides an improved absorption of calcium glycerophosphate into the airway of the subject.

### Claim 9 (depends on 1)

The method of claim 1, wherein the calcium glycerophosphate is administered to the subject by a nasal drop, a nasal spray, a nasal lavage, an inhaled powder, a mechanized intermittent fluid pulser, an inhaler, a respirator, a transpirator, an atomizer, a vaporizer, an air mask, a means for direct physical or mechanical application, or an insufflator.

### Claim 10 (depends on 1)

The method of claim 1, wherein the calcium glycerophosphate is administered to the subject using a metered dose inhaler (MDI), a dry powder inhaler (DPI), a nebulizer, or a cotton swab.

### Claim 11 (depends on 1)

The method of claim 1, further comprising administering to the respiratory system of the subject an analgesic.

### Claim 12 (depends on 11)

The method of claim 11, wherein the analgesic is selected from the group consisting of ibuprofen, acetominophen, aspirin, naproxen, and capsaicin.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject is a human subject selected from the group consisting of a pediatric patient, an elderly patient, a pregnant woman, and a patient who has frequent need of a relief agent and/or preventive agent for the disease, disorder and/or condition of the respiratory system.

### Claim 14 (depends on 1)

The method of claim 1, further comprising administering to the respiratory system of the subject one or more medications for a disease, disorder and/or condition of the respiratory system.

### Claim 15 (depends on 14)

The method of claim 14, wherein the one or more medications are selected from the group consisting of a beta-2 agonist, a long-acting beta-2-agonist (“LABA”), an inhaled corticosteroid, an alpha agonist, a bronchodialator, a glucocorticoid, a leukotriene modifier, a mast cell stabilizer, an antimuscarinic/anticholinergic, a methylxanthine, an antihistamine, omalizumab, methotrexate, tianeptine, albuterol, and cromolyn.

### Claim 16

A method of reducing, interdicting and/or repairing irritation to the respiratory system of a subject by an agent administered to the respiratory system of the subject, the method comprising:
a. administering the agent to the respiratory system of the subject; and
b. administering an effective amount of calcium glycerophosphate to the respiratory system of the subject in a dosage of about 440 μg to about 88 mg of the calcium glycerophosphate per administration,
wherein the effective amount of calcium glycerophosphate reduces, interdicts and/or repairs irritation to the respiratory system of the subject by the agent.

### Claim 17 (depends on 16)

The method of claim 16, wherein the agent and the calcium glycerophosphate are administered simultaneously or sequentially to the respiratory system of the subject.

### Claim 18 (depends on 16)

The method of claim 16, wherein the agent and the calcium glycerophosphate are administered to the respiratory system of the subject in separate formulations.

### Claim 19 (depends on 16)

The method of claim 16, wherein the calcium glycerophosphate is administered to the subject in a composition comprising about 0.05%-10% (w/w) calcium glycerophosphate.

### Claim 20 (depends on 19)

The method of claim 19, wherein the composition comprises about 0.5%-7.5% (w/w) calcium glycerophosphate.
